Composition and method for reducing levels of inflammatory mediators

A synergistic approach using AKBA and hydroxytyrosol addresses the limitations of existing inflammation treatments by reducing TNF-α and other mediators, effectively managing chronic inflammation and tissue damage without side effects.

JP2024166415AActive Publication Date: 2024-11-28NUTRAMAX LABORATORIES INC
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2024163552
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-10-04
Filing Date
2024-09-20
Publication Date
2024-11-28
Estimated Expiration
2037-04-21

AI Technical Summary

Technical Problem

Current treatments for managing inflammation, such as osteoarthritis, often rely on non-steroidal anti-inflammatory drugs (NSAIDs) that cause side effects, and targeted therapies for TNF-α can have undesirable consequences, necessitating alternative methods to modulate pro-inflammatory mediators like PGE2 and TNF-α without inhibiting their physiological functions.

Method used

Administering a combination of 3-O-acetyl-11-keto-β-boswellic acid (AKBA) and hydroxytyrosol, derived from Boswellia serrata and olive extracts respectively, to mammals and birds, in specific dosages to synergistically reduce levels of inflammatory mediators and alleviate connective tissue damage.

Benefits of technology

The combination of AKBA and hydroxytyrosol effectively reduces TNF-α production and other inflammatory mediators, providing therapeutic benefits without the side effects of NSAIDs and maintaining physiological functions, thus addressing chronic inflammation and associated tissue damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166415000001_ABST
    Figure 2024166415000001_ABST
Patent Text Reader

Abstract

To provide a composition and a method configured to alleviate pain, discomfort, pressure, inflammation, tension, and / or a feeling of swelling associated with connective tissue damage caused by inflammatory mediators.SOLUTION: Hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid are used in combination. The hydroxytyrosol may be sourced from olive extract and the 3-O-acetyl-11-keto-β-boswellic acid may be sourced from Boswellia serrata extract.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Related Applications

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 403,807, filed October 4, 2016, and incorporates by reference the entire disclosure of that application. [Technical field]

[0002] The present invention provides a method for administering (i) 3-O-acetyl-11-keto-β-boswellic acid (AKBA) and (ii) hydroxytyrosol to a mammal or bird, and also provides an orally administrable composition comprising AKBA and hydroxytyrosol. [Background technology]

[0003] Connective tissue is the structural framework of cartilage, bone, synovium, ligaments, meniscus, and tendons in joints. Connective tissue components are produced and secreted by resident cells, and they provide the properties of the extracellular matrix (ECM) of the tissue. In addition to acting as a structural framework, the ECM plays a critical role in cellular signaling and function. In articular cartilage, chondrocytes are arranged in a distinct pattern within the type II collagen ECM structure. Bone-forming osteoblasts and osteocytes, as well as bone-resorbing osteoclasts, are organized in a mineralized type I collagen ECM. Some fibroblast-like and macrophage-like cells in the synovium are also held in place by the ECM. Similarly, tendon and ligament cells are arranged within the ECM. The synthesis and degradation of connective tissue ECM is controlled by a network of regulatory molecules produced by resident tissue cells. This network includes numerous molecules known as growth factors and proinflammatory mediators.

[0004] These mediators include cytokines, chemokines, prostaglandins and nitric oxide. These molecules exhibit numerous biological activities, inducing cell proliferation or cell death. They can also induce anabolic pathways that generate ECM and catabolic enzymes that can degrade ECM. Under physiological conditions, cell survival or death, and the production or degradation of connective tissue ECM, are tightly regulated to maintain a balanced homeostasis. The production and function of regulatory molecules are modulated by many factors, including mechanical forces, physical factors such as temperature and pH, chemicals, microorganisms and their products. Under certain conditions, these factors can lead to excessive and premature production of regulatory molecules, resulting in irreparable tissue damage, loss of function and cell death.

[0005] Tissues respond to mechanical, physical, and chemical factors and infections with an inflammatory response. The inflammatory process is known to contribute to recovery, healing, defense against infection, and preservation of life. In humans and animals, the inflammatory response consists of two phases. The first phase is characterized by the local synthesis of pro-inflammatory mediators, such as prostaglandins and leukotrienes, which are derived from arachidonic acid through the action of cyclooxygenase and lipoxygenase. These pro-inflammatory mediators increase local blood flow, endothelial cell permeability, and leukocyte recruitment and accumulation. Further proinflammatory mediators that are subsequently produced include cytokines (interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), chemokines (IL-8) and nitric oxide). In the second, or resolution, phase, prostaglandins produced during the first phase activate enzymatic pathways that convert arachidonic acid into chemical mediators with anti-inflammatory properties. Prostaglandin E2 (PGE2) reportedly activates the expression of 15-lipoxygenase, which produces anti-inflammatory lipoxins from arachidonic acid. Thus, resolution of inflammation is promoted by the proinflammatory response. These studies show that the initiation, progression and termination of the inflammatory response are tightly regulated. Prolonged and exacerbated inflammation leads to the development of numerous disorders, such as osteoarthritis (OA), rheumatoid arthritis (RA), Alzheimer's disease and cardiovascular disease.

[0006] In articular tissues, chondrocytes, synovial cells, osteoblasts, osteoclasts, ligament cells and tendon cells produce numerous proinflammatory mediators. Among these is PGE2, which is known to play a regulatory role by inducing the production of other mediators, including cytokines, nitric oxide and connective tissue degradation metalloproteinase (MMP) enzymes. PGE2 can induce metalloproteinases (MMPs), thus contributing to the degradation of cartilage ECM. Furthermore, PGE2 promotes bone resorption and osteophyte formation. PGE2 sensitizes nociceptors in peripheral nerve endings, exacerbating inflammatory pain. PGE2 levels can be locally regulated by the cyclooxygenase-2 (COX-2) enzyme. In pathological conditions such as osteoarthritis, COX-2 expression is up-regulated, with a concomitant increase in PGE2 production.

[0007] TNF-α is a major mediator of inflammation and plays an important role in tissue regeneration / expansion and degradation during inflammation, and under normal conditions, inflammation is well regulated by these factors, i.e., after inflammation is caused by these factors and the accompanying immune response is induced, the levels of these factors decrease to normal levels, but unregulated production of TNF-α leads to chronic inflammation and directly leads to various diseases such as arthritis.

[0008] Although inflammation is a necessary and important immunological process for the resolution of tissue injury and infection, chronic release of proinflammatory mediators such as IL-1β and TNF-α leads to the subsequent production of additional inflammatory mediators, and if levels are not restored to normal, dysregulated production of TNF-α can potentially lead to deleterious pathophysiological processes such as osteoarthritis (OA).

[0009] TNF-α plays a key role in initiating the inflammatory process. TNF-α is produced by various cells present in the joint: chondrocytes, osteoblasts, cells in the synovium, immune cells resident in the joint, or cells that infiltrate the joint during the inflammatory response. Elevated levels of TNF-α can be detected in the synovial fluid, synovium, ligaments, and subchondral bone of patients with osteoarthritis.

[0010] TNF-α can induce nuclear factor-kappa B (NF-κB), a key regulator of inflammatory responses, together with IL-1β. TNF-α induces the production of PGE2 by increasing the production of key enzymes involved in PGE2 synthesis, including COX-2, microsomal PGE synthase (mPGES-1), and soluble phospholipase A2 (sPLA2). In addition, TNF-α induces the production of inducible nitric oxide synthase (iNOS), resulting in high levels of nitric oxide (NO). The production of other cytokines, including IL-6, IL-17, and IL-18, and the chemokine IL-8, are also significantly modulated by TNF-α. The combined production of these proinflammatory mediators, namely prostaglandins, NO, cytokines, and chemokines, ultimately leads to the fracture of cartilage in osteoarthritic conditions.

[0011] TNF-α can suppress the synthesis of two key components of the extracellular matrix: aggrecan and type II collagen. In addition, TNF-α induces the expression of aggrecanases ADAMTS4 and ADAMTS-5, enzymes that degrade aggrecan. These two actions combine to disrupt the normal biochemical balance between synthesis and degradation of cartilage matrix in the joint, ultimately resulting in cartilage degradation. TNF-α is also associated with mitochondrial dysfunction, low ATP production, and apoptosis, which may also play a role in causing cartilage degradation. Although TNF-α plays a central role in initiating essential immune responses to injury and infection, the deleterious effects it triggers when dysregulated make it a target for the development of inflammation management drugs.

[0012] The role of other tissues in the inflammatory process has also been established. Synovial inflammation is now recognized as a key feature in osteoarthritis, especially in the early stages of osteoarthritis, in cartilage degradation. Synovitis is characterized by the activation of resident macrophage-like and fibroblast-like cells in the synovium, which produce excessive amounts of proinflammatory mediators, including TNF-α, IL-1β, and PGE2. Recent evidence suggests that synovial macrophages are the primary source of cytokines in the earliest stages of osteoarthritis and that these macrophages are important contributors to cartilage damage throughout the progression of osteoarthritis. Cytokines also induce the production of PGE2 and active metalloproteinases (MMPs). It is now widely recognized that these mediators control the balance between ECM degradation and repair, and through this recognition, these molecules have become preferred targets for therapeutic intervention. Other tissues within the joint, such as the subchondral bone, also produce proinflammatory mediators that modulate joint health.

[0013] In addition to proinflammatory mediators such as cytokines and prostaglandins, reactive oxygen species (ROS) also play a role in the joint degradation seen in osteoarthritis. Oxidative stress induced by ROS, including nitric oxide and hydrogen peroxide, has been shown to be responsible for chondrocyte apoptosis and cartilage ECM degradation. Furthermore, ROS reportedly activate signaling pathways that lead to increased production of proinflammatory mediators, including cytokines and prostaglandins. Test-tube studies have demonstrated coupling between pathways involved in the production of ROS and proinflammatory mediators. These studies support the idea that drugs that can suppress both oxidative stress and inflammatory pathways would be particularly useful in modulating inflammation.

[0014] The central role of COX-2 and PGE2 in the pathophysiology of osteoarthritis is reflected in the widespread use of selective COX-2 inhibitors and a variety of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) to treat the disorder. However, chronic use of these drugs results in side effects including gastrointestinal pathology and disruption of cartilage proteoglycan metabolism. Studies in human and animal models have demonstrated that the use of COX inhibitors promotes healing and repair of damaged bone. Thus, there is a need for alternative approaches to inflammation management that are not centered around the use of NSAIDs and that suppress the production of PGE2 and other proinflammatory mediators, including TNF-α.

[0015] Drugs that have been developed to target TNF-α include Infliximab (a chimeric monoclonal antibody against human TNF), Adalimumab (a fully human monoclonal antibody), Etanercept (a dimeric TNFRII (p75) fusion protein bound to the Fc portion of human IgG), Golimumab, CDP571, and Thalidomide. However, these drugs not only suppress the positive functions of TNF-α, but also may cause undesirable outcomes, including the development of lymphoma and infection. Thus, there is a need for therapeutic agents that can regulate the excessive generation of reactive oxygen species and cell death induced by TNF-α without inhibiting the positive physiological functions of TNF-α. [Prior art documents] [Patent documents]

[0016] [Patent Document 1] WO2001 / 045514 A1 [Patent Document 2] WO2002 / 018310 A1 [Patent Document 3] WO2004 / 005228 A1 [Patent Document 4] WO2010 / 029578 A2 [Patent Document 5] US2002 / 0004077 A1 [Patent Document 6] US2002 / 0058078 A1 [Patent Document 7] US2002 / 0198415 A1 [Patent Document 8] US2004 / 0039066 A1 [Patent Document 9] USP6,361,803 [Patent Document 10] USP6,416,808 [Patent Document 11] EP1582512 A1 [Non-patent literature]

[0017] [Non-Patent Document 1] Gonzalez-Santiago, et al., Pharmacological research, 61.4(2010):364-370 [Non-Patent Document 2] Sengupta, et al.Molecular and cellular biochemistry, 354.1-2(2011):189-197 Summary of the Invention

[0018] According to the object and effect of the present invention, the first aspect of the present invention provides a synergistic composition of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid. In an embodiment, the source of hydroxytyrosol is an olive extract and the source of 3-O-acetyl-11-keto-β-boswellic acid is a Boswellia serrata extract. The composition can be formulated for oral administration to a mammalian subject. The mammal can be selected from the group consisting of humans, dogs, cats, horses, camels or cattle. In another embodiment, the composition can be formulated for oral administration to an avian subject.

[0019] In an embodiment, a composition formulated for oral administration to a human may have 3-O-acetyl-11-keto-β-boswellic acid in an amount of about 0.67 mg to about 2.70 mg per kg of body weight and hydroxytyrosol in an amount of about 0.15 mg to about 2.50 mg per kg of body weight. In an embodiment, a composition formulated for oral administration to a dog may have 3-O-acetyl-11-keto-β-boswellic acid in an amount of about 1.24 mg to about 4.98 mg per kg of body weight and hydroxytyrosol in an amount of about 0.28 mg to about 4.60 mg per kg of body weight.

[0020] Another aspect of the present invention provides a method for treating, repairing or alleviating connective tissue damage caused by one or more inflammatory mediators by administering to a mammal or bird in need thereof an orally administrable synergistic composition of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid as described above.

[0021] Yet another aspect of the present invention provides a method for reducing the levels of one or more inflammatory mediators in connective tissue by administering to a mammal or bird in need thereof an orally administrable composition of a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid as described above.

[0022] Hereinafter, the embodiments of the composition and method of the present invention will be described. It should be understood that the composition and method of the present invention can be implemented in different embodiments, and the details can be modified in various obvious ways without departing from the scope of the claims. In other words, the accompanying drawings and description are merely illustrative and are not intended to be limiting. [Brief description of the drawings]

[0023] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the disclosed compositions and, together with the disclosure, serve to explain certain principles of the inventive compositions.

[0024] [Figure 1] 1 shows the effect of constant concentrations of hydroxytyrosol and AKBA on TNF-α production in lipopolysaccharide-stimulated RAW264.7 mouse macrophage cells. [Diagram 2] 1 shows the effect of constant concentrations of hydroxytyrosol and AKBA on TNF-α production in lipopolysaccharide-stimulated RAW264.7 mouse macrophage cells. [Diagram 3] 1 shows the effect of constant concentrations of hydroxytyrosol and AKBA on TNF-α production in lipopolysaccharide-stimulated RAW264.7 mouse macrophage cells.

[0025] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Reference will now be made in detail to the embodiments of the compositions and corresponding methods of the present invention, examples of which are illustrated in the accompanying drawings. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] The present invention provides a method for administering (i) 3-O-acetyl-11-keto-β-boswellic acid (AKBA) and (ii) hydroxytyrosol to a mammal or bird. The AKBA and hydroxytyrosol may be administered simultaneously in a single composition or dosage form, or may be administered separately. In some embodiments, the AKBA and hydroxytyrosol are administered simultaneously or separately in a single composition or dosage form during a period of overlap in their therapeutic properties. In some embodiments, the compositions are administered separately within one hour of each other. In other embodiments, the compositions are administered separately within 30 minutes of each other. In still other embodiments, the compositions are administered separately within five minutes of each other.

[0027] As used herein, the term "mammal" refers to any mammal, including, but not limited to, humans, dogs, cats, horses, cows, and camels, and the term "avian" refers to birds.

[0028] Hydroxytyrosol is a phenolic phytochemical found in various parts of the olive tree. Its IUPAC name is 4-(2-hydroxyethyl)-1,2-benzenediol, and it has the following structural formula: TIFF2024166415000002.tif52126

[0029] In the present invention, hydroxytyrosol may be synthetic or derived from natural sources, such as products or by-products derived from olive trees by extraction and / or purification. Additionally, hydroxytyrosol may be administered in the form of a hydroxytyrosol-containing extract that can be obtained from products or by-products derived from olive trees. Products or by-products derived from olive trees include, but are not limited to, olives (olive fruit), olive leaves, olive pulp, olive oil, olive-derived vegetation water, and olive oil sediment. Based on the extraction method, a person skilled in the art should be able to easily adjust the amount of hydroxytyrosol and the respective ratios. In an embodiment, hydroxytyrosol is derived from olives, which can be obtained from conventional commercially available sources, such as producers.

[0030] Hydroxytyrosol for use in the present invention can be produced by many methods known in the art. Olives can be processed by any suitable means to obtain the composition for use in the present invention. For example, olives and / or olive leaves can be pressed to obtain a mixture containing olive oil, vegetation water and solid by-products. Hydroxytyrosol can be obtained directly from this mixture or the mixture can be fractionated and / or purified to obtain hydroxytyrosol. Fractionation and / or purification of the composition can be carried out by many methods known to those skilled in the art. Examples of fractionation methods include partitioning using organic solvents, chromatography, high pressure liquid chromatography (HPLC) and the use of supercritical fluids.

[0031] References for the extraction of hydroxytyrosol from olive leaves are WO02 / 18310 A1, US2002 / 0198415 A1, WO2004 / 005228 A1, USP6,416,808 and US2002 / 0058078 A1, which all disclose a method of acid hydrolysis of olive vegetation water for 2 to 12 months until at least 90% of oleuropein is converted. Methods for the extraction of hydroxytyrosol from olives, olive pulp, olive oil and wastewater from oil refineries are disclosed in USP6,361,803, WO01 / 45514 A1 and US2002 / 0004077 A1. EP1582512 A1 discloses the extraction of hydroxytyrosol from olive leaves. Paragraphs

[0080] to

[0091] of US2004 / 0039066 A1 disclose a method for obtaining hydroxytyrosol from vegetation water of olives that have not had their pits removed.

[0032] Likewise, commercially available hydroxytyrosol-containing olive extracts are suitable for use in the present invention.

[0033] The literature reports that oral bioavailability of hydroxytyrosol was observed in humans at a single dose of 2.5 mg / kg, with peak plasma concentrations observed of 1.11 ± 0.20 μMmol / L. Gonzalez-Santiago, et al., Pharmacological research, 61.4 (2010), pp. 364-370, states that dosage calculations can be determined by one skilled in the art by assessing body weight, surface area, and species differences. Similarly, dosages subject to interspecies extrapolation can be calculated by one skilled in the art using routine dosage conversion methods.

[0034] A typical dosage of hydroxytyrosol is about 0.001 mg / kg to about 2.0 mg / kg. In some embodiments, for humans and non-human animals, a typical daily dosage is at least 0.1 mg to no more than 300 mg, where daily dosage refers to the total dosage administered in a 24-hour period.

[0035] In some exemplary embodiments, for human subjects, the dosage of hydroxytyrosol may be set at 0.15-2.50 mg per kg of body weight (i.e., 9-250 mg for a 60 kg human subject).

[0036] In some exemplary embodiments, when the subject is a dog, the dosage of hydroxytyrosol may be set at 0.28 mg to 4.60 mg per kg of body weight (i.e., 2.8 to 46 mg for a 10 kg dog).

[0037] The hydroxytyrosol may be administered from once a week to five times a day. In one embodiment, the hydroxytyrosol is administered from once every two days to three times a day. In yet another embodiment, the hydroxytyrosol is administered from once to twice a day. In yet another embodiment, the hydroxytyrosol is administered once a day. Hydroxytyrosol may be administered with or without feeding.

[0038] Phytochemicals extracted from Boswellia serrata have been reported to be active in treating a number of diseases and ailments. The gum resin of Boswellia serrata has been used for many years by Ayurvedic practitioners in the Indian system of medicine to treat rheumatoid arthritis and gout. Various extracts of the gum resin have shown potential anti-inflammatory and anti-atherosclerotic activity in experimental animals. The biological activity of the extracts is related to the composition of the boswellic acid fraction. 3-O-acetyl-11-keto-β-boswellic acid (AKBA) has been identified as the most active compound in Boswellia serrata extracts. Boswellia serrata extracts containing AKBA have been reported to inhibit 5-lipoxygenase and matrix metalloproteinase-3 (MMP-3) in vitro as described in WO2010 / 029578 A2. Similarly, WO2010 / 029578 A2 reports on the anti-inflammatory efficacy of a composition having an extract of Boswellia serrata selectively enriched in AKBA by up to 30% in vivo, including a significant reduction in serum biomarkers TNF-α and IL-1β.

[0039] The literature also reports on the bioavailability of a single dose of 100 mg / kg of Boswellia serrata extract standardized to 30% AKBA in rat serum. It is reported that a peak serum concentration of 2.0 μg / mL was observed. Sengupta, et al. Molecular and cellular biochemistry, 354.1-2 (2011): 189-197. Dosage calculations can be determined by one skilled in the art by assessing body weight, surface area, and species differences. Similarly, dosages subject to interspecies extrapolation can be calculated by one skilled in the art using routine dosage conversion methods.

[0040] A typical dosage of AKBA is about 0.01 mg / kg to about 10.0 mg / kg. In some embodiments, for humans and non-human animals, a typical daily dosage is at least 1 mg to about 1 g or less. Here, a daily dosage refers to the total dosage administered in a 24-hour period.

[0041] In some exemplary embodiments, for human subjects, the dosage of AKBA can be set at 0.67 to 2.70 mg per kg of body weight (i.e., 40 to 162 mg for a human weighing 60 kg).

[0042] In some exemplary embodiments, when the subject is a dog, the dosage of AKBA can be set at 1.24 to 4.98 mg per kg of body weight (i.e., 12.4 to 49.8 mg for a dog weighing 10 kg).

[0043] The AKBA can be administered from once a week to five times a day. In some embodiments, the AKBA can be administered from once every two days to three times a day. In yet other embodiments, the AKBA can be administered from once to twice a day. In yet other embodiments, the AKBA can be administered once a day. The AKBA can be administered with or without feeding.

[0044] Some embodiments demonstrate that the combination of (i) hydroxytyrosol and (ii) AKBA exhibits a synergistic effect, where synergy refers to the effect of two or more ingredients used together to produce a result that is greater than the sum of the effects of each ingredient when used alone. In some embodiments, the result is statistically significant and is greater than an additive effect. In some embodiments, the combination of hydroxytyrosol and AKBA produces a statistically significant effect that is greater than the effect of each ingredient when used alone. In some embodiments, the combination of hydroxytyrosol and AKBA produces one or more of the following synergistic effects: prevention, treatment, repair, or mitigation of damage to connective tissue; mitigation of symptoms associated with connective tissue damage in birds and mammals; and reduction of the levels of one or more inflammatory mediators in connective tissue.

[0045] The present invention provides a method for preventing, treating, repairing, or alleviating damage, or inhibiting inflammation of connective tissue, protecting cartilage, or alleviating symptoms associated with connective tissue damage in birds and mammals, by administering (i) hydroxytyrosol and (ii) AKBA to a subject. As used herein, the term "connective tissue" includes, but is not limited to, cartilage, bone, synovium, ligaments, menisci, and tendons. In some embodiments, administration of (i) hydroxytyrosol and (ii) AKBA can prevent, treat, repair, or alleviate connective tissue damage. Connective tissue damage can occur as a result of physical injury or can manifest as "wear and tear" caused by continued use, weight, and age. Examples include osteoarthritis. Connective tissue damage can also be the cause of diseases such as rheumatoid arthritis, synovial disorders, infections associated with rheumatic diseases, and inflammatory connective tissue disorders. In some embodiments, administration of (i) hydroxytyrosol and (ii) AKBA can alleviate symptoms associated with connective tissue damage in birds and mammals. Symptoms associated with connective tissue damage include, but are not limited to, pain, discomfort, pressure, inflammation, tightness and / or swelling.

[0046] The present invention also provides a method for reducing the levels of one or more inflammatory mediators in connective tissue by administering to a bird or mammal (i) hydroxytyrosol and (ii) AKBA. Inflammatory mediators include, but are not limited to, tumor necrosis factor-α (TNF-α), prostaglandins such as prostaglandin E2 (PGE2), cytokines such as interleukin-1β (IL-1β), chemokines, leukotrienes, nitric oxide, and reactive oxygen species.

[0047] Administration of hydroxytyrosol and AKBA is also useful for treating, preventing and alleviating injury and symptoms associated with conditions affecting the cardiovascular, nervous, musculoskeletal and gastrointestinal systems. In one embodiment, the invention provides compositions and methods for preventing and / or alleviating inflammatory responses and / or inflammation in a subject. In one embodiment, the invention provides compositions and methods for managing inflammatory disorders or for reducing the overall inflammatory burden in humans and non-human animals. Thus, in one embodiment, the invention provides a method for preventing and / or alleviating inflammatory responses and / or inflammation in one or more tissues by delivering a composition of the invention to the one or more tissues.

[0048] The present invention also provides an orally administrable composition having (i) hydroxytyrosol and (ii) AKBA. The orally administrable composition may take any orally administrable dosage form, including, but not limited to, capsules, tablets, powders dispersible in beverages, pastes in pelletized form, liquids such as solutions, suspensions and emulsions, soft gel / chewable capsules, chewable bars and other convenient dosage forms such as encapsulated oral liquids known in the art.

[0049] Orally administrable compositions may contain one or more non-active pharmaceutical ingredients (also commonly known as "excipients") that, for example, solubilize, suspend, thicken, dilute, emulsify, stabilize, preserve, protect, color, flavor, and ultimately formulate the active ingredients into a ingestible and efficacious preparation that is safe, convenient, and otherwise acceptable for use. The excipients may be any pharma- ceutically acceptable excipient. Examples of types of pharma- ceutically acceptable excipients include lubricants, buffers, stabilizers, foaming agents, pigments, colorants, flavoring agents, fillers, bulking agents, fragrances, release modifiers, adjuvants, plasticizers, flow promoters, release agents, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, anti-adherents, acidulants, softeners, resins, analgesics, solvents, surfactants, emulsifiers, elastomers, and mixtures thereof.

[0050] Orally administrable compositions may further comprise one or more active ingredients. For example, the composition may further comprise one or more pharmaceutical agents or nutritional supplements. In some embodiments, the composition may further comprise a compound beneficial to connective tissue. Examples include, but are not limited to, glycosaminoglycans such as chondroitin, amino sugars such as glucosamine, methylsulfonylmethane (MSM), collagen (including collagen type II), green tea extract, scutellaria extract, acacia extract, turmeric extract, curcumin, cetylmyristolein complex (CMO), and eggshell membrane.

[0051] All references cited herein are incorporated by reference in their entirety. EXAMPLES

[0052] Example 1: Effects of hydroxytyrosol and AKBA on TNF-α production in lipopolysaccharide (LPS)-stimulated RAW264.7 mouse macrophage cells

[0053] RAW264.7 mouse macrophage cells were pretreated for 24 hours with 60 nM, 160 nM or 1 μM hydroxytyrosol (HT) (98% purity, Sigma-Aldrich, St. Louis, MO) alone, 0.28 μg / mL, 0.56 μg / mL or 1.124 μg / mL AKBA (administered as 5-LOXIN® standardized to 30% AKBA, PLT Health Solutions) alone, or with each of the three concentrations of HT in combination with each of the three concentrations of AKBA. Cells were then stimulated for an additional 24 hours with 1 μg / mL lipopolysaccharide (LPS). LPS is an endotoxin present in bacterial cell walls and can induce an inflammatory response that increases the production of TNF-α. Cell supernatants were analyzed for TNF-α production. Statistical comparisons were performed using one-way analysis of variance (ANOVA) with Tukey post-hoc analysis, with P<0.05 considered significant. Data are presented as mean + / - 1SD.

[0054] A statistically significant greater reduction in TNF-α levels was observed when each of the three concentrations of HT was combined with AKBA than when either was used alone. Combination of 60 nM HT with either 0.28 μg / mL, 0.56 μg / mL, or 1.124 μg / mL AKBA reduced TNF-α production to a greater extent than HT (P<0.001) or AKBA (P<0.001) alone (Figure 1). The reduction in TNF-α in cells treated with 160 nM HT combined with 0.56 μg / mL AKBA was statistically significant greater than that of HT (P<0.001) or AKBA (P=0.001) alone (Figure 2). Cells treated with 1 μM HT in combination with 0.28 μg / mL, 0.56 μg / mL, or 1.124 μg / mL AKBA showed a statistically significant reduction in TNF-α compared with HT alone (P<0.001, P=0.002, and P<0.001, respectively) and compared with AKBA alone (P<0.001, P=0.002, and P=0.004, respectively) (Figure 3).

Claims

1. A composition configured for relieving pain, discomfort, pressure, inflammation, tightness and / or swelling associated with connective tissue damage caused by one or more inflammatory mediators, comprising a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid in amounts that prevent or reduce inflammatory responses in the connective tissue of a subject in need thereof.

2. the source of hydroxytyrosol is at least one of an olive extract, a product obtained from an olive tree, or a by-product obtained from an olive tree; 2. The composition of claim 1, wherein the source of 3-O-acetyl-11-keto-β-boswellic acid is an extract of Boswellia serrata.

3. 10. The composition of claim 1 formulated for oral administration to a mammalian or avian subject.

4. 4. The composition of claim 3, wherein said mammal is selected from the group consisting of a human, a dog, a cat, a horse, a camel, or a cow.

5. 5. The composition of claim 4, wherein the composition formulated for oral administration to a human subject has 3-O-acetyl-11-keto-β-boswellic acid in an amount of about 0.67 mg / kg to about 2.70 mg / kg of body weight, and the composition formulated for oral administration to a dog subject has 3-O-acetyl-11-keto-β-boswellic acid in an amount of about 1.24 mg / kg to about 4.98 mg / kg of body weight.

6. 5. The composition of claim 4, wherein the composition formulated for oral administration to a human subject has hydroxytyrosol in an amount of about 0.15 mg to about 2.50 mg per kg of body weight, and wherein the composition formulated for oral administration to a dog subject has hydroxytyrosol in an amount of about 0.28 mg to about 4.60 mg per kg of body weight.

7. The composition of claim 1, wherein said hydroxytyrosol and said 3-O-acetyl-11-keto-β-boswellic acid are administered together to said subject animal as a single composition.

8. The composition of claim 1, wherein said hydroxytyrosol and said 3-O-acetyl-11-keto-β-boswellic acid are administered separately to said subject within one hour.

9. The composition of claim 1, wherein said hydroxytyrosol and said 3-O-acetyl-11-keto-β-boswellic acid are administered separately to said subject within 30 minutes.

10. The composition of claim 1, wherein said hydroxytyrosol and said 3-O-acetyl-11-keto-β-boswellic acid are administered separately to said subject within 5 minutes.

11. 1. A method for relieving pain, discomfort, pressure, inflammation, tightness and / or swelling associated with connective tissue damage caused by one or more inflammatory mediators, comprising administering to a non-human subject in need thereof a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid in amounts that reduce the levels of one or more inflammatory mediators in the connective tissue of the non-human subject.

12. the source of hydroxytyrosol is at least one of an olive extract, a product obtained from an olive tree, or a by-product obtained from an olive tree; 12. The method of claim 11, wherein the source of 3-O-acetyl-11-keto-β-boswellic acid is an extract of Boswellia serrata.

13. 12. The method of claim 11, wherein the composition is administered to a non-human mammal or avian subject and is formulated for oral administration.

14. 14. The composition of claim 13, wherein the non-human mammal is selected from the group consisting of a dog, a cat, a horse, a camel, or a cow.

15. 14. The method of claim 13, wherein said hydroxytyrosol and said 3-O-acetyl-11-keto-β-boswellic acid are administered together as a single composition.

16. The method according to claim 13, wherein the hydroxytyrosol and the 3-O-acetyl-11-keto-β-boswellic acid are administered separately within one hour.

17. The method according to claim 13, wherein the hydroxytyrosol and the 3-O-acetyl-11-keto-β-boswellic acid are administered separately within 30 minutes.

18. The method according to claim 13, wherein the hydroxytyrosol and the 3-O-acetyl-11-keto-β-boswellic acid are administered separately within 5 minutes.

Citation Information

Patent Citations

  • Chinese medicinal composition for treating rheumatoid arthritis

    CN102451428A

  • Synergistic Anti-inflammatory compositions comprising boswellia serrata extract

    US20150290270A1

  • Olive compositions and methods for treating inflammatory conditions

    WO2006020588A1

  • Compositions and use thereof for the treatment, co-treatment or prevention of imflammatory disorders

    WO2008006581A2

  • Process for obtaining hydroxytyrosol from olive leaves extracts

    EP1582512A1